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AbsTrACT
background The autoimmune disease systemic lupus 
erythematosus (SLE) occurs more frequently in patients of 
African descent with high morbidity and mortality. Current 
SLE diagnostic criteria including antinuclear antibody (ANA) 
reactivity are derived largely from non-African populations. 
This study characterises ANA reactivity patterns and 
relates them to SLE clinical presentation in Black African 
patients.
Methods Sera from Black participants (61 patients with 
SLE and 100 controls) aged 1–81 years were analysed 
for reactivity against the antigens: uridine 1-ribonuclear 
protein, Smith uridine-1-5 ribonuclear protein antigen, 
soluble substance-A, recombinant Ro-52, soluble 
substance-B, Scl-70, cytoplasmic histidyl-tRNA synthetase 
antigen, proliferating cell nuclear antigen (PCNA), 
nucleosomes, ribonuclear P-protein, antimitochondrial 
antibody M2 (AMA-M2), histones, double-stranded DNA 
(dsDNA), centromere protein B and polymyositis–sclerosis 
overlap antigen.
Findings A significantly higher proportion (97%) of the 61 
patients with SLE had detectable autoantibody reactivity 
compared with 15% of the 100 controls (p<0.001). The 
highest frequencies of autoantibody reactivity in patients 
with SLE were against the dsDNA antigen (41%) and PCNA 
(54%). Anti-PCNA and anti-dsDNA reactivity were mutually 
exclusive (p<0.001) giving rise to two distinct groups of 
Black African patients with SLE. The first group (n=25) had 
reactivity profiles consistent with international standard 
SLE definitions, including anti-dsDNA reactivity, and was 
13 times more likely to present with joint symptoms. The 
larger, second group (n=34), characterised by anti-PCNA 
and anti-AMA-M2 reactivity, was nine times more likely to 
present with only cutaneous symptoms.
Interpretation Our study demonstrates a need to extend 
autoantibody panels to include anti-PCNA in the diagnostic 
process of Black African patients and further refine the 
predictive values of the reactivity to different antigens to 
differentiate SLE syndromes in African populations.
InTroduCTIon
Systemic lupus erythematosus (SLE) is a 
complex, chronic autoimmune disease that 
can affect multiple organs including the skin, 
joints, haematopoietic system, kidneys, lungs 
and the central nervous system.1 Previous 
studies report differences in the preva-
lence and severity of SLE in different ethnic 
groups.2 SLE-associated mortality in Black 
American patients is 24% compared with 5% 
among Asians with comparable demographic 
and clinical features.3 SLE diagnosis in Africa 
remains challenging and true disease and 
mortality rates are unknown.4 Treatment is 
often complicated by side effects,5 so accu-
rate, and early diagnosis (which can be facil-
itated by characterising autoantibody reac-
tivity) is key to successful disease manage-
ment.6 Current SLE diagnostic criteria were 
defined through collaborations including 
the American Rheumatism Association 
Key questions
What is already known?
 ► Systemic lupus erythematosus (SLE) occurs more 
frequently in patients of African descent but the 
scientific basis for SLE diagnostic criteria is derived 
from non-African populations.
 ► Refining the predictive values of antinulcear anti-
body subtype reactivity to different nuclear antigens 
will aid differentiation of SLE syndromes in African 
populations.
What are the new findings?
 ► Our key finding is that there exists a large subgroup 
(54%) of Southern African patients whose laboratory 
tests differ from the international American College 
of Rheumatology Classification diagnostic guidelines 
for SLE.
 ► This group did not react against dsDNA, but rather 
were reactive against proliferating cell nuclear anti-
gen (PCNA) and was nine times more likely to pres-
ent with only cutaneous symptoms.
What do the new findings imply?
 ► Our findings show that there is a need to consid-
er the two antinuclear antigens, PCNA and antim-
itochondrial antibody M2, as additional diagnostic 
markers for patients with SLE.
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(ARA)7 8 and the Systemic Lupus International Collabo-
rating Clinics Classification (SLICC)9 whose criteria are 
now referred to as the American College of Rheuma-
tology (ACR) criteria.7 8 Even though SLE occurs more 
frequently in patients of African descent,10 the scientific 
basis for SLE classification is derived predominantly from 
studies in non-African populations. The revised criteria 
for SLE classification includes detection of antinuclear 
antibodies (ANA) and extractable nuclear antibodies 
(ENA)11 which mediate the disease and are associated 
with distinct SLE disease subsets and progression.12 13 
Autoantibody production is influenced by, among other 
factors, human leucocyte antigen (HLA) haplotype,14 
with the HLA haplotype believed to influence disease 
prevalence, for example, increased rates of SLE in Afri-
can-Americans and more frequent detection of SLE in 
first-degree relatives15 16compared with unrelated people. 
The biomarkers of SLE may differ in different racial 
populations, for example, patients of African ancestry 
are reportedly more likely to have anti-Sm antibodies 
compared with those of European ancestry.17 
Studies validating the SLICC SLE diagnostic criteria 
(eg, Petri et al 9) have not included Black patients resi-
dent in Africa. In addition, the epidemiology of SLE in 
Africa remains largely unknown. The disease is under-
reported in Africa due to several reasons that include 
poor access to healthcare, low disease recognition within 
primary healthcare settings, limited access to diagnostic 
tools and inadequate numbers of relevant specialists.4 To 
help address some of these issues, we have conducted this 
study to inform SLE diagnosis in Africa through char-
acterisation of autoantibody reactivity profiles in Black 
African patients with SLE and relating their autoantibody 
reactivity to clinical symptoms.
MeTHods
Patients and controls
This retrospective study consisted of 161 participants 
aged 1–81 years. All patients had been referred to the 
Asthma, Allergy and Immune Dysfunction Clinic in 
Harare, Zimbabwe, for diagnosis and management of 
suspected allergic, immunodeficiency or autoimmune 
conditions during the period between July 2010 and April 
2014. Ethical approval for the study was obtained from 
the Medical Research Council of Zimbabwe and written 
informed consent to use results of clinical assessment for 
research was obtained from the participants/guardians 
as appropriate. All participants were permanent resi-
dents in Zimbabwe and they self-reported ethnicity in 
terms of race as Black, White, Asian or mixed race. Given 
the sample size available for the other ethnicities, only 
Black African participants were included in the study. 
The clinician (ES) conducted case history collation and 
clinical examination of all participants. For inclusion into 
the study, participants had to be negative for HIV infec-
tion and be permanent residents of Zimbabwe. Data were 
anonymised through assignment of unique identification 
numbers for each patient prior to transferring for anal-
ysis. Of the 161 participants, 61 who fulfilled the ACR 
criteria8 were diagnosed as positive for SLE.
The 100 controls represent patients who were negative 
for any autoimmune disease or allergic disease. These 
patients had been referred to the clinic for investigation 
of allergy and were tested and clinically evaluated for 
both allergy and autoimmune diseases and were found 
negative for both. They were tested at the same period 
as the SLE cases but have a slightly larger range of ages 
(1–81 vs 2–67 years for cases). To ensure that no results 
were attributable to differences in gender or age range, 
we carried out two further analyses using age-matched 
and gender-matched patients with SLE and controls at 
both a 1:1 and 2:1 ratio of controls to patients and calcu-
lated the proportions reacting to the different nuclear 
and mitochondrial antigens. The results were consistent 
across all analyses, and therefore, 61 SLE cases and 100 
controls were included in the study. The gender and sex 
distributions of the participants are given in table 1.
Clinical and laboratory assessment
A diagnosis of SLE was made based on the patient’s clinical 
history, symptoms at presentation (eg, figure 1) and rele-
vant laboratory investigations. All participants fulfilling the 
ACR criteria for SLE were categorised as positive for SLE. 
Analysis for sero-reactivity against the nuclear and mito-
chondrial antigens was conducted for all 61 patients with 
SLE and the 100 controls. In 52 of the patients with SLE, 
the disease stage did not require repeated evaluation thus 
autoantibody reactivity was assessed once.  All these  patients 
were offered routine clinical monitoring to guide labora-
tory investigations. The remaining nine patients with SLE 
were followed up at least twice in 4 years. While asthma and 
rhinitis symptoms are not features of SLE, the conditions 
are not mutually exclusive and some of the patients with 
SLE presented with these comorbidities. These and any 
other comorbidities were recorded and included in the 
statistical analyses. Laboratory tests were guided by clinical 
Table 1 Study population
Clinical 
diagnosis N
Median 
age 
(years)
Minimum 
age 
(years)
Maximum 
age 
(years)
Controls 
  Female 70 28.0 1 81
  Male 30 14.5 1 79
  Total 100 27.0* 1 81
SLE 
  Female 42 30.5 2 67
  Male 19 38.0 2 52
  Total 61 34.0* 2 67
*Statistical comparison of the distribution of ages between 
the patients with SLE and the controls showed no significant 
difference (Mann-Whitney test, p=0.240).
SLE, systemic lupus erythematosus.
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presentation and medical history. These included haema-
tology, biochemistry, serology and immunology, (immuno-
globulin (Ig)A, IgM and IgG reactivity to a panel of nuclear 
antigens, complement (C3 and C4)), erythrocyte sedimen-
tation rate, C reactive protein, cardiolipin and glycoprotein 
determination.
Autoantibody reactivity determination
Patients’ serum samples were analysed using a commer-
cially available ANA Profile 3 Euroline Cat # DL 1590-
6401-3 G immunoblot kit containing the 15 autoantigens 
listed in table 2, following the manufacturer’s instruc-
tions. This kit has previously been used successfully 
either together with conventional indirect immuno-
fluorescence for comparison, or alone to characterise 
connective tissue or autoimmune diseases.18–21 Briefly, 
immunoblot test strips impregnated with 15 antigens 
were incubated with sera diluted at 1:101 in a sample 
buffer. In reactive samples, serum antibodies bind to 
their respective autoantigenic sites. The bound autoanti-
bodies are detected by incubating the strips with alkaline 
phosphatase labelled anti-human IgG antisera. The addi-
tion of the substrate elicits a colour reaction evaluated 
visually and semiquantitatively using the manufacturer’s 
software (EUROlabScan) to indicate positive or negative 
reactivity. A control band is included in each strip.
statistical analysis
Reactivity results for the 15 autoantigens were recorded 
as presence or absence. Test results from (n=11) patients 
with follow-up visits (from 2 to 4) were combined for the 
purposes of analysis: auto antibodies against the antigen 
were considered present if detected during at least one visit. 
The frequency of autoantibody reactivity for patients with 
SLE versus controls was compared using the Fisher’s exact 
test. The frequency of reactivity was <5% against CENP-B, 
Jo-1, PM-Scl, Scl-70, nRNP/Sm and SS-B and >5% for SS-A, 
Sm, Ro-52, PCNA, nucleosomes, Rib. P-protein, histones, 
dsDNA and AMA-M2. Associations across all antigens 
(except anti-CENP-B where no patients were reactive) were 
examined using tetrachoric correlations (Proc freq, SAS 
V.9.4), (online supplementary table S1).
Autoantibody reactivity was further characterised in 
the patients with SLE using two-way cluster analysis (PC 
ORD V.6.0822)employing Jaccard distance and Group 
average method to generate clusters. Two out of the 61 
patients were not included in the analyses, as they were 
not reactive to any of the antigens. The number of signif-
icant clusters was determined by creating different levels 
of clustering (n=2–8 clusters) within the dendogram and 
plotting the distance between each cluster.12 The number 
of clusters was determined by breakpoint analysis. There-
after, cluster designation was used to determine associa-
tions with clinical symptoms using either Fisher’s exact 
test or Χ2 analysis depending on the structure of the data. 
Clinical symptoms from patients were partitioned into 
five summary groups: cutaneous, joint, asthma and rhini-
tis-like, gastrointestinal and other (online supplementary 
table S2). Statistical significance was set a priori at p<0.05. 
To check whether there may be subgroups within clus-
ters, the two clusters obtained were divided into smaller 
groups and the association tests run to determine if the 
groups had different associations with the clinical signs. 
There were no significant differences within the main 
clusters with respect to the association with clinical signs 
and therefore, the two clusters were maintained.
The frequency of autoantibody reactivity among patients 
with SLE was compared with reference frequencies 
published from other populations11 23–26 and from test 
populations used for validating the diagnostic kit by the kit 
manufacturer (https://www. euroimmun. com/? id= 2589).
Figure 1 Photographs of patients’ physical symptoms. 
(A) Non-scarring, non-atrophic patchy hair loss, alopaecia 
areata in a 14-year-old boy with SLE (dsDNA+). (B) Diffuse 
thinning and loss of hair in a 45-year-old woman (dsDNA+). 
(C) A 36-year-old woman with a rash involving the malar area 
and nose, sparing the naso-labial folds (SLE butterfly rash) 
(dsDNA−; PCNA−). (D) A 54-year-old woman with scaring 
alopaecia of the scalp, and scaring lesions on the ear lobes 
and parts of the face (PCNA+). (E) A 13-year-old girl with 
non-scarring photosensitive dermatitis of the neck and face 
(PCNA+). dsDNA, double-stranded DNA; PCNA, roliferating 
cell nuclear antigen; SLE, systemic lupus erythematosus. 
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resulTs
Autoantibody reactivity profile
A significantly higher proportion (97%) of the 61 patients 
with SLE were autoantibody reactive compared with 15% 
of the 100 controls (Fisher’s exact=123, df=1, p<0.001). 
The autoantibodies detected in the 15% control partic-
ipants were directed against one or more of the nuclear 
antigens nRNP/Sm, Sm, SS-A, Ro-52, Jo-1, PM-Scl 
and AMA-M2, with frequencies predominantly <5% 
(figure 2, online supplementary table S3). The highest 
frequencies of autoantibody reactivity in patients with 
SLE were against dsDNA (41%) and PCNA (54%). Two 
patients who fulfilled the ACR clinical criteria for SLE 
diagnosis showed no autoantibody reactivity.
Correlations between autoantibody reactivity
The correlations among the autoantibody reactivi-
ties in patients with SLE were analysed and results are 
shown in the online supplementary table S1. Analysis of 
autoantibody reactivity to the nine antigens with reac-
tivity frequency >5% showed several significant correla-
tions (figure 3). Nucleosomes and histones were tightly 
Table 2 Antinuclear antigens on the diagnostic test strip
Antigen Immunoblot assay kit manufacture’s detail
nRNP/Sm Uridine 1-ribonuclear protein (U1-nRN) purified by affinity chromatography from calf and rabbit thymus
Sm Smith uridine-1-5 ribonuclear protein antigen purified by affinity chromatography from bovine spleen and 
thymus. The Sm antigen contains the core proteins of snRNP particles. D protein is the main component of the 
Sm preparation
SS-A Soluble substance-A (60 kDa) purified by affinity chromatography from bovine spleen and thymus
Ro-52 Recombinant Ro-52 (52 kDa). The corresponding human cDNA has been expressed with the baculovirus 
system in insect cells
SS-B Soluble substance-B antigen purified by affinity chromatography from calf and rabbit thymus
Scl-70 DNA topoisomerase antigen purified by affinity chromatography from bovine and rabbit thymus
PM-Scl Polymyositis–sclerosis overlap antigen. Recombinant PM-Scl100 whose corresponding human cDNA has been 
expressed with the baculovirus system in insect cells
Jo-1 Cytoplasmic histidyl-tRNA synthetase antigen purified by affinity chromatography from calf and rabbit thymus
CENP-B Recombinant centromere protein B whose corresponding human cDNA has been expressed with the 
baculovirus system in insect cells
PCNA Proliferating cell nuclear antigen. Recombinant PCNA (36 kDa) whose corresponding human cDNA has been 
expressed with the baculovirus system in insect cells
dsDNA Double-stranded DNA. The highly purified native, double-stranded DNA was isolated from salmon testes
Nucleosomes Native nucleosomes purified from calf thymus
Histones A mixture of individually purified histone types isolated from calf thymus
Rib. P-protein Ribosomal P proteins purified by affinity chromatography
AMA-M2 Purified antimitochondrial M2 (pyruvate–dehydrogenase complex) antigen
Figure 2 Proportion of participants diagnosed with SLE (n=61) and study control patients (n=100) who are reactive against 
each antinuclear antigens. AMA-M2, antimitochondrial antigen M2; CENP-B, centromere protein B; dsDNA, double-stranded 
DNA; Jo-1, cytoplasmic histidyl-tRNA synthetase antigen; nRNP/Sm, uridine 1-ribonuclear protein; PCNA, proliferating cell 
nuclear antigen; PM-Scl, polymyositis–sclerosis overlap antigen; Rib. P-protein, ribosomal P protein; Ro-52, recombinant Ro-
52; SLE, systemic lupus erythematosus; Sm, Smith uridine-1-5 ribonuclear protein antigen; SS-A, soluble substance-A; SS-B, 
soluble substance-B. 
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correlated (r=1, p<0.001) although the sample sizes of 
reactive patients was low for nucleosomes n=3 compared 
with n=10 for histones. There was a negative correlation 
between Sm (n=6) and SSA (n=8) (r= −0.97, p<0.001). 
The most outstanding result was a strong negative corre-
lation between anti-dsDNA (n=25) and anti-PCNA reac-
tivity (n=33) (r=−1.0, p=0.008, figure 3). No patient 
expressed both anti-dsDNA and anti-PCNA autoantibody 
reactivity. Data from 9 patients with SLE (n=4 dsDNA 
reactive, and n=5 PCNA reactive) with follow-up testing 
showed that patients did not switch between the expres-
sion of anti-dsDNA versus anti-PCNA autoreactivity.
relating autoantibody reactivity profiles to clinical 
presentation in patients with sle
Two-way cluster analysis identified two main groups: 
cluster 1 and cluster 2 (figure 4) based on the autoan-
tibody reactivity profiles of patients with SLE. Cluster 1 
comprised 25 patients; all were reactive against dsDNA 
but not the PCNA. Cluster 2 comprised 34 patients; 33 
reactive against PCNA but not reactive against dsDNA and 
1 that was not reactive against either dsDNA or PCNA. 
The expression of anti-dsDNA and anti-PCNA reactivity 
was mutually exclusive. More cluster 2 patients reacted 
against the mitochondrial antigen AMA-M2 compared 
with patients with SLE in cluster 1 (p=0.028).
Associations between cluster and clinical symptoms 
(online supplementary table S2) showed that cluster 
1 was significantly associated with synovitis, arthritis 
or arthralgia (p=0.008; OR=12.8; 95% CI 1.41 to 595) 
(online supplementary table S3). Although patients in 
both clusters had cutaneous symptoms, patients in cluster 
Figure 3 Figure showing the tetrachoric correlation 
coefficients for nine dichotomous autoantibodies with 
reactivity frequency >5% among the patients with 
SLE (n=61). AMA-M2, antimitochondrial antigen M2; 
dsDNA, double-stranded DNA; nRNP/Sm, uridine 
1-ribonuclear protein; PCNA, proliferating cell nuclear 
antigen; Ro-52, recombinant Ro-52; SLE, systemic lupus 
erythematosus; Sm, Smith uridine-1-5 ribonuclear protein 
antigen; SS-A, soluble substance-A. 
Figure 4 Two-way cluster analysis dendogram of patients 
with SLE (n=59, with two patients showing no ANA 
subtype reactivity excluded). Only the ANA subtypes with 
reactivity >5% reactivity frequency were included. The matrix 
of shaded squares represents the patient ×ANA reactivity 
matrix, while the dendrograms show the clustering. The 
dendrograms are scaled by Wishart’s objective function, 
expressed as the percentage of information remaining 
at each level of grouping.22 Each square represents the 
presence (black) and absence (white) of a reaction with 
a given biomarker. Two main clusters (designated 1 and 
2) were identified. Matrix also indicates the presence of 
clinical symptoms with the colour key: blue=cutaneous 
symptoms; green=joint symptoms; purple=asthma and 
rhinitis-like symptoms; turquoise=gastrointestinal symptoms; 
yellow=other symptoms. AMA-M2, antimitochondrial 
antigen M2; ANA, antinulcear antibody; dsDNA, double-
stranded DNA; nRNP/Sm, uridine 1-ribonuclear protein; 
PCNA, proliferating cell nuclear antigen; Ro-52, recombinant 
Ro-52; SLE, systemic lupus erythematosus; Sm, Smith 
uridine-1-5 ribonuclear protein antigen; SS-A, soluble 
substance-A. 
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2 were significantly more likely to have only cutaneous 
symptoms (p=0.003; OR =9.1; 95% CI 1.71 to 88.6).
Comparison of autoantibody reactivity profile of black 
patients with sle to reference ranges
The frequency or autoantibody reactivity directed against 
each antigen in the SLE patients was compared with 
the reference ranges published for SLE patients from 
different populations11 23–26 (figure 5, online supplemen-
tary table S4). The SLE patients were divided into the 
clusters identified in the cluster analysis. The frequency 
of PCNA, AMA-M2 and dsDNA reactivity was similar to the 
reference ranges for cluster one patients only. Patients in 
cluster two had a much higher reactivity frequency for 
both PCNA and AMA-M2 and a much lower reactivity 
frequency for dsDNA. Overall, the reactivity frequency 
patterns of Cluster one patients were similar though not 
identical to the published ranges, whereas Cluster two 
patients had a distinct autoantibody reactivity frequency 
pattern compared with the published ranges (figure 5).
dIsCussIon
Differences in SLE incidence and prevalence between 
different ethnic and racial groups have previously been 
documented in Americans in the United States11 26 27 and 
more recently in South Africans.23 Despite these ethnic 
differences, there is limited information regarding the 
frequency of antibody reactivity to different antigens 
among different races and ethnicities. Given the impact 
of both the environment and genetics on SLE incidence 
and possibly variable patterns of progression,23 there is 
need for SLE studies in Africa. Even in studies previously 
conducted in Black or African populations, for example, 
in Zimbabwe,28 29 Cameroon30 and South Africa,23 31 the 
nuclear antigens evaluated were often limited to dsDNA 
alone as the ACR recommended antigen associated with 
SLE. Here, the sero-reactivities of patients with SLE to a 
range of nuclear and mitochondrial antigens were char-
acterised in a Black African population to inform diag-
nosis of SLE in Black patients resident in Africa.
As expected, significantly more patients with SLE 
were ANA reactive as assessed by immunoblot analysis 
of ANA subtype reactivity, compared with the controls 
diagnosed negative for any connective tissue or allergic 
disease by clinical history and examination. The antim-
itochondrial antigen AMA-2 is associated with Primary 
Biliary Cirrhosis is not routinely determined in SLE. It 
was measured in this study because it was part of the 
manufacturer’s autoantibody strip. Nonetheless, in this 
study, the high frequency of anti-AMA-M2 reactivity in 
both the SLE-negative participants and some patients 
with SLE is intriguing. Although some tropical infec-
tious diseases, for example, malaria, hepatitis B and 
tuberculosis, induce ANA reactivity,32 in this group, 
no participants (patients or controls) were diagnosed 
with these infections. Two participants clinically diag-
nosed patients with SLE did not show any ANA subtype 
reactivity. This is not unusual since autoreactivity can 
mirror disease severity and SLE clinical presentation 
in the absence of ANA reactivity is known to occur in 
about 5% of patients with SLE.33 In view of the profile 
and patient scope of the clinic, it was not surprising 
that a number of the patients with SLE had allergy-re-
lated symptoms in addition to having SLE, however 
sample sizes of this group were too small to conduct 
any statistical analyses.
Correlation analyses showed different relationships 
between reactivities against different nuclear antigens. 
The outstanding novel results, the strong negative 
correlation between dsDNA, the hallmark SLE autoan-
tigen34 and PCNA with the groups of patients reacting 
against these two antigens, were mutually exclusive.
Figure 5 Comparison of reactivity frequency between patients with SLE and published reference ranges. Mean proportion of 
patients (n=61) positive for reactivity against the 15 ANA subtypes along with their exact 95% CIs. Data for the patients were 
divided into the two clusters identified in figure 4. Cluster 1 (blue) includes patients reacting primarily to dsDNA. Cluster 2 (red) 
includes patients reacting primarily with PCNA. Proportion of the reference population (recognised criteria11 23–26) is in black. 
Reference values: dots represent only a single value found for reference ANA frequency; bars represent lowest and highest 
in the range of values found for the reference. AMA-M2, antimitochondrial antigen M2; ANA, antinulcear antibody; CENP-B, 
centromere protein B; dsDNA, double-stranded DNA; Jo-1, cytoplasmic histidyl-tRNA synthetase antigen; nRNP/Sm, uridine 
1-ribonuclear protein; PCNA, proliferating cell nuclear antigen; PM-Scl, polymyositis–sclerosis overlap antigen; Rib. P-protein, 
ribosomal P protein; Ro-52, recombinant Ro-52; SLE, systemic lupus erythematosus; Sm, Smith uridine-1-5 ribonuclear protein 
antigen; SS-A, soluble substance-A; SS-B, soluble substance-B. 
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Forty-one per cent of the patients with SLE in the study 
were reactive against the dsDNA antigen, a frequency 
within the published range of 40%–90%.11 The only 
previous ANA study in Zimbabwe showed a 100% dsDNA 
reactivity frequency among patients with SLE, but that 
study tested just seven Black patients.29 The reactivity 
profile of the dsDNA-reactive patients with SLE in this 
present study was largely similar to frequency ranges 
published for other African or African American popula-
tions, including those from the large retrospective study 
of Tunisians,35 South Africans23 and African Americans26 
and it was consistent with the 2012 SLICC criteria9 for 
SLE. Fifty-four percent of the patients with SLE were 
negative for reactivity against dsDNA, but were reactive 
against PCNA. This is notably higher than 1%–3%36 or 
5%–10%34 PCNA frequencies reported in the litera-
ture. The age ranges between the dsDNA and PCNA reac-
tive groups were similar so that age was not a determinant 
of ANA reactivity pattern. In addition, none of the nine 
patients who followed up two to four times during the 
4-year study period switched their autoantibody reactivity 
between these two antigens.
PCNA reactivity has been reported as expressed in 
patients with SLE with a very high specificity (99%).36–38 
It is remarkable that while the literature reports the 
presence of anti-PCNA reactivity in only a handful of 
patients,34 36 the proportion reported in this study was 
considerably higher.
Further analysis showed that patients with SLE fell into 
one of two distinct clinical clusters. The first subgroup 
(44% of these patients) generally follows the revised ACR 
and SLICC SLE classifications with ANA subtype profile 
anchored by anti-dsDNA reactivity. This group was 13 
times more likely to present with synovitis and tended to 
have a severe clinical course with frequent mucosal, joint 
and renal involvement. It is interesting to note that the 
published studies in Black African patients with SLE that 
have reported a high frequency of anti-dsDNA antibodies, 
for example, 67%, 100% and 74% in Black South Afri-
cans,31 Zimbabweans29 and Cameroonians30 respectively, 
have also reported high levels of joint clinical symptoms 
(arthritis), that is, 62%, 81% and 64% of the population, 
respectively. It is therefore possible that these studies are 
reporting the form of SLE present in the dsDNA-reactive 
patients, that is, those in cluster 1.
The second group (56%) of patients with SLE had 
an autoantibody reactivity profile characterised by anti-
PCNA. An associated antigen in this patient group was 
anti-AMA-M2 which is a characteristic of primary biliary 
cirrhosis.39–41 The patients in this study did not have any 
clinical or laboratory features of primary biliary cirrhosis 
or autoimmune hepatitis. Their liver enzymes alanine 
transaminase, aspartate aminotransferase, alkaline phos-
phatase and albumin were normal. The PCNA subtype 
reactivity profile has not previously been described at 
such a high frequency in the literature nor have the 
PCNA reactivity frequencies and association with cuta-
neous symptoms previously been reported in African 
populations. This subgroup was nine times more likely 
to present with cutaneous symptoms including pruritic, 
annular or papulosquamous dermatoses that healed 
without scarring as seen in some forms of cutaneous lupus 
erythematosus (CLE).42 The coexpression of anti-PCNA 
and AMA-M2 reactivity may be indicative of a subgroup of 
patients with the cutaneous variant of lupus and warrants 
further investigation. There is need to explore whether 
genetic variants in the HLA region explain the existence 
of the two identified clusters. There were other associa-
tions between, for example, histones and Sm in patients 
with SLE positive for anti-PCNA reactivity, but sample 
sizes were too small to make any conclusive interpreta-
tions. These relationships and their biological meaning 
require further explorations in larger sample sizes.
A recent initiative to inform SLE management in 
African patients (the African Lupus Genetics Network) 
identified underdiagnosis/delayed diagnosis as chal-
lenges to care delivery.4 A Zimbabwean study reported 
that inclusion of the ANA reactivity (dsDNA and Sm) 
increased the sensitivity of the SLE diagnostic criteria.28 
Thus, the inclusion of PCNA may further inform these 
diagnostic criteria and improve sensitivity. Given these 
data, a prospective study of patients with SLE will allow 
more detailed characterisation of the immunology and 
molecular features of the Zimbabwean patients. This will 
overcome the constraints/biases of retrospective studies.
In conclusion, our study suggests that there exists a large 
subgroup (~50%) of Southern African patients whose 
ANA subtype reactivity is directed against the PCNA. This 
profile differs from the ACR and SLICC classification of 
SLE which only recommend testing for the anti-dsDNA 
and anti-Sm antibodies. The findings suggest that a reli-
ance on the ACR laboratory criteria for SLE diagnosis 
may not be adequate for all patient groups residing in 
Africa. Furthermore, anti-PCNA antibodies may be a 
marker for cutaneous variants of SLE. Our study shows 
a need to (i) widen the panel of diagnostic antinuclear 
and anti-mitochondrial antigens used in African patients, 
(ii) further refine the predictive values of the ANA reac-
tivity to different nuclear and mitochondrial antigens in 
order to differentiate SLE syndromes in African popula-
tions, and (iii) consider anti-PCNA reactivity, which has 
so far been largely excluded in Africa and elsewhere,43 as 
a diagnostic marker for patients with SLE.
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